Here’s what’s making waves in AI today:

Former OpenAI chief scientist Ilya Sutskever is making a bold $30 billion bet on artificial superintelligence (ASI) with his startup, Safe Superintelligence Inc. (SSI). With no revenue or commercial product, SSI is attracting massive investment, signaling confidence in Sutskever’s alternative approach to AI development.

In today’s Generative AI Newsletter:

• Ilya Sutskever’s $30B ASI Startup – A radical new AI vision with no plans for commercialization.

• Google Scrubs ‘Diversity’ & ‘Equity’ From AI Ethics Page – A quiet but major shift in AI fairness policies.

• Stanford AI’s Ozempic Alternative – A natural weight-loss breakthrough with fewer side effects.

AI is moving fast—let’s break down the biggest stories shaping the future.

Navigating AI Regulations: ISO 42001 & EU AI Act Explained

As AI evolves, so do the regulations. Join Vanta’s upcoming webinar with AWS and Prescient Security to explore key frameworks like ISO 42001 and the EU AI Act, essential for any organization working with AI in the EU.

In this session, you'll learn:

• How to ensure your AI and security practices meet top standards

• Key provisions of ISO 42001 and the EU AI Act and their impact on your organization

• Practical strategies for seamless compliance

Don’t miss this opportunity to stay ahead of AI regulations and register today! Can't make it live? Register anyways and we'll send you a recording.

🗺️ Ex-OpenAI Scientist’s $30B Bet on ASI

Former OpenAI chief scientist Ilya Sutskever is charting a new course toward artificial superintelligence (ASI) with his startup, Safe Superintelligence Inc. (SSI). Despite having no revenue or public product, SSI is reportedly raising $2 billion at a staggering $30 billion valuation, signaling investor confidence in Sutskever’s contrarian approach to AI development.

💡 Why It Matters:

• A Radical New AI Path – Sutskever describes his approach as “a different mountain to climb”, suggesting a fundamental shift away from traditional AI scaling methods.

• Massive Valuation Without Revenue – SSI is seeking $30 billion valuation, even before launching a commercial product—an unprecedented move in AI investment.

• No Plans for Commercialization – Unlike OpenAI and DeepMind, SSI is focused solely on achieving superintelligence before releasing any AI-powered applications.

Sutskever’s departure from OpenAI came after the Sam Altman ouster saga, and his new venture signals a different vision for AI’s future. Will SSI redefine the path to ASI, or is this a high-stakes bet on an uncertain future?

🔍 Google Scrubs ‘Diversity’ and ‘Equity’ From AI Ethics Page

Google has quietly removed references to “diversity” and “equity” from its Responsible AI and Human-Centered Technology (RAI-HCT) team’s webpage, signaling a shift in its public stance on AI fairness and inclusivity. The move follows the company’s broader rollback of diversity, equity, and inclusion (DEI) initiatives.

💡 Why It Matters:

• AI Ethics Without DEI? – Google’s RAI-HCT team, responsible for AI safety and fairness, no longer explicitly references marginalized or underrepresented groups in its mission.

• A Broader Industry Trend – Big Tech companies, including Amazon, Meta, and OpenAI, have also reduced DEI efforts in response to political and legal pressure in the U.S.

• Government Contracts in Play – Many of these companies, including Google, hold major federal contracts, raising questions about whether these policy changes are tied to compliance concerns.

With Apple resisting pressure to scale back DEI, the tech industry remains divided on its approach. Is this the end of Big Tech’s DEI era, or just a strategic pivot?

💊 Stanford AI Uncovers Natural Weight-Loss Molecule

Stanford researchers have identified BRP, a naturally occurring molecule that mimics Ozempic’s weight-loss effects without its common side effects—thanks to AI-powered drug discovery. This breakthrough could reshape obesity treatment by offering a safer, more targeted alternative.

💡 Why It Matters:

• AI-Powered Discovery – Stanford’s Peptide Predictor AI analyzed 20,000 human genes to pinpoint BRP as a potent appetite suppressant.

• No Ozempic-Like Side Effects – Unlike semaglutide, BRP avoids nausea, muscle loss, and digestive issues by acting directly on the brain’s hypothalamus.

• Promising Early Results – In animal studies, a single dose halved food intake, with obese mice losing significant fat over two weeks.

A startup is already preparing human trials, marking a potential game-changer in weight-loss treatments.

🚀 Boost your business with us—advertise where 10M+ AI leaders engage

🌟 Sign up for the first AI Hub in the world.

📲 Our Socials